Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04511520
Other study ID # PTAF02-02/13
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 2013
Est. completion date April 2017

Study information

Verified date May 2021
Source National Medical Research Center for Therapy and Preventive Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atrial fibrillation (AF) is one of the most common forms of heart rhythm disorder in patients with cardiovascular diseases. The choice of treatment for AF is a complex problem, depending on the form (paroxysmal, persistent, permanent) of AF, clinical manifestations of cardiac arrhythmias, associated diseases, the effectiveness of antiarrhythmic drugs. The accumulated data to date indicate an efficacy of the method of radiofrequency ablation (RFA) in the treatment of the paroxysmal form of AF. The RFA procedure does not eliminate the pathological processes that take place during developed AF. This dictates the need to develop and test new technologies and physical rehabilitation programmes for patients. The positive clinical effects of physical rehabilitation programmes based on moderate-intensity exercises are well known. The search for drugs capable of improving the results of RFA for AF in patients becomes urgent. This creates the prerequisites for the study of the clinical efficacy of trimetazidine MV in the rehabilitation of patients with cardiac diseases who underwent treatment of AF with RFA, which will optimize the management of such patients in the inpatient and outpatient setting.


Description:

The study is interventional (Clinical Trial), randomized in parallel groups. Enrollment: 72 participants. The 72 male patients were randomized in 3 groups. In 1st group (control) patients were taken antiarrhythmical drugs and anticoagulants. They did only usual activity without walking. Patients in 2nd group were taken antiarrhythmical drugs and anticoagulants, participated in rehabilitation programme. Twice a week they came in clinical center to engage in physical training with an instructor. The programe was lasted for 6 months. Also patients did they usual physical activity, practiced walking. Patients in 3rd group were taken antiarrhythmical drugs and anticoagulants, selective inhibitor of fat acids oxidation for 6 months. They did only usual activity without walking. The examination was carried for all 72 patients. Before RFA patients took blood tests, performed echocardiography, completed psychological questionnaires. After 3 days they took blood tests, performed 6-minute walk testing, ECG monitoring, completed psychological questionnaires. One month after RFA patient performed veloergometry testing. Three months after RFA the performed 6-minute walk testing, ECG monitoring, took blood tests, completed psychological questionnaires. Six months after RFA patients took blood tests, performed echocardiography, 6-minute walk testing, ECG monitoring, veloergometry testing, completed psychological questionnaires. Onward was a follow up period for 6 months. At the time point of 12 months patients took blood tests, performed echocardiography, ECG monitoring, veloergometry testing, completed psychological questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date April 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Male
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - treated for atrial fibrillation with radiofrequency ablation - cardiac disease - providing written informed consent Exclusion Criteria: - Congenital and acquired heart defects. - Acute coronary syndrome (unstable angina, myocardial infarction), myocardial revascularization during the previous 6 months - Transient ischemic attack, stroke in history. - Arterial hypertension (BP =160/100 ??. ??. ??.) - The risk of thromboembolic complications on a scale CHA2DS2-VASc> 2 - Risk of hemorrhagic complications of anticoagulant therapy (HAS-BLED> 3 points on the scale). - Complications after RFA. - Chronic heart failure above III FC (NYHA), ejection fraction (EF) <40%. - Acute thrombophlebitis, complicated forms of varicose veins (thrombophlebitis, phlebothrombosis). - Pronounced atherosclerosis of peripheral arteries (intermittent claudication), requiring surgical intervention. - Violation of conductivity: AV-blockade 2-3 degrees, complete blockade of the bundle of the His bundle - The presence of an implanted pacemaker pacemaker / pacemaker with a resynchronization function/cardioverter-defibrillator) - Conduct RFA on AF earlier. - The presence of a history of syncopal states. - Diabetes mellitus type 1 and 2 in the stage of decompensation. - Acute conditions: infection, exacerbation of chronic diseases in a period of less than 1 month prior to the study; severe injury, surgical interventions other than RFA for a period of less than 2 months from the start of the study - Renal failure (creatinine levels above 300 µmol / L or 3.5 mg / dL). - Patient's refusal to participate in the study - Alcohol and drug abuse. - Peptic ulcer and duodenal ulcer in history. - Obesity, body mass index (BMI) =40 kg / m2 - Intake of Trimetazidine MB and its analogues for 3 months. before inclusion in research. - The presence of any disease that, according to the doctor, prevents the inclusion of the patient in the study. - unable to understand study instructions - with considerable illness in the musculoskeletal system or with physical disability, which complicates exercise training

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical training program

Drug:
Trimetazidine


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Research Center for Preventive Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Atrial Fibrillation Recurrence Number of participants with reccurrence of atrial fibrillation after RFA From RFA to 3 months
Primary Atrial Fibrillation Recurrence Number of participants with recurrence of atrial fibrillation after RFA From 3 months to 6 months
Primary Atrial Fibrillation Recurrence Number of participants with recurrence of atrial fibrillation after RFA From 6 months to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT06085014 - Clinical and Electrophysiological Predictors of Arrhythmic Recurrence in Patients With Paroxysmal AF Undergoing First Ablation Procedure of AF by Pulmonary Vein Isolation
Recruiting NCT03724383 - Atrial Fibrillation Lifestyle Project N/A
Active, not recruiting NCT04544397 - Outcomes of Second Generation Laser Balloon Ablation for Atrial Fibrillation
Not yet recruiting NCT05940597 - Pulsed Field Ablation vs Cryoablation In Paroxysmal Atrial Fibrillation N/A
Not yet recruiting NCT04447300 - Outcomes of High Power Application in Catheter Ablation of Paroxysmal Atrial Fibrillation Guided by Unipolar Signal Modification. N/A
Recruiting NCT05251545 - Randomized Trial: High Power Short Duration Versus Ablation Index N/A
Recruiting NCT05883631 - RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy. N/A
Not yet recruiting NCT04600713 - Physiotherapist-led Exercise Within Cardiac Rehabilitation and Paroxysmal Atrial Fibrillation and COVID-19. N/A
Enrolling by invitation NCT05725187 - Prospective Validation Study of AI-based Prediction Algorithm for the Prediction of Paroxysmal Atrial Fibrillation
Recruiting NCT04606693 - Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates N/A
Recruiting NCT05328882 - Early Recurrences of Atrial Arrhythmias and Their Impact on Late Recurrence After Pulmonary Vein Isolation With Pulsed Field Ablation of Paroxysmal Atrial Fibrillation
Recruiting NCT04342312 - Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation
Recruiting NCT05549752 - Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia Phase 3
Completed NCT03323099 - Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation N/A
Completed NCT05461859 - Cardioneuroablation for the Treatment of Vagally-mediated Atrial Fibrillation.
Enrolling by invitation NCT04634461 - The Relationship Between Panic Attack Symptoms and Atrial Fibrillation Episodes.
Completed NCT04023461 - Isolation of Pulmonary Veins With PVAC GOLD in Elderly Patients Phase 4
Recruiting NCT06392932 - Esophageal Temperature During PVI Using Q-DOT Micro N/A
Not yet recruiting NCT06364215 - Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation N/A
Recruiting NCT05292209 - RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring Phase 2